Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (August 2018)

42 slides from Windtree Therapeutics's investor presentation, Aug 27, 2018

  1. Slide 1: Corporate Presentation August 2018

    Se Ze WINDTREE Corporate Presentation August 2018 OTCQB:WINT

  2. Slide 2: Forward-looking Statement

    Forward-looking Statement To the extent that statements in this presentation are not strictly historical, including statements about the Company’s clinical development programs, business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreem

  3. Slide 3: Windtree Therapeutics

    Windtree Therapeutics = Public, small cap biopharmaceutical / medical device company = Based in Warrington, PA with 27 employees = Focused on acute markets with a lead program expected to address a significant need and significantly expand the Respiratory Distress Syndrome (RDS) in premature infants

  4. Slide 4: Respiratory Distress Syndrome (RDS)

    Respiratory Distress Syndrome (RDS) Primary characteristic is surfactant deficiency in underdeveloped lungs of premature infants (born with a lack of natural lung surfactant required for open airways and proper gas exchange — O, in and CO, out) American Academy of Pediatrics guidelines recommend pro

  5. Slide 5: Prevalence of RDS Spans Across Gestational Ages / Severity

    Prevalence of RDS Spans Across Gestational Ages / Severity % of RDS Population RDS Prevalence i <26 weeks GA >95% 26-28 weeks GA 85-95% AEROSURF® Clinical Development Program @ 29-32 weeks GA 65-75% 33-34 weeks GA 40-50% 35-36 weeks GA 5-10% LOWER Size of Sub-Population HIGHER 30% nCPAP 4+ line 55%

  6. Slide 6: Current RDS Treatment Pathways

    Current RDS Treatment Pathways Initial treatment options include invasive and non-invasive methods: Surfactant Invasive mechanical nCPAP Support until presumptive Therapy + ventilation (IMV) endogenous surfactant production * Animal-derived surfactant | + Requires sustained + Non-invasive nasal deli

  7. Slide 7: Clinicians Seeking a Noninvasive Way to Deliver Surfactant

    Clinicians Seeking a Noninvasive Way to Deliver Surfactant What is wanted: Vv Avoid the risks and complications associated with delivery of surfactant therapy via intubation and mechanical ventilation Y Possibility of repeat doses Y Avoid clinical instability associated with administration of liquid

  8. Slide 8: Windtree Technology Platform - AEROSURF

    Windtree Technology Platform - AEROSURF® Potential to Provide Both Non-Invasive and Invasive Solutions to Treat RDS Proprietary Synthetic KL4 Surfactant Designed to be structurally similar to human Designed specifically to aerosolize lung surfactant and deliver KLa surfactant Liquid KL surfactant (i

  9. Slide 9: Transformative Potential of AEROSURF

    Transformative Potential of AEROSURF® Surfactant Therapy ncPAP Respiratory Support RISKS respiration Surfactant therapy delivers near-immediate clinical improvement Reversing surfactant deficieney.has /a profound positive impact on\ BPD Infection, ventilator-induced pneumonia cord damage, asthma, lu

  10. Slide 10: Potential Drivers of AEROSURF Opportunity

    Potential Drivers of AEROSURF® Opportunity #1 stated unmet need in RDS 20-30% reduction in nCPAP failure is meaningful “Noninvasive Results in >40% surfactant delivery” reported = 54% top, unaided expected response (3x higher , patient share~ than next response) 1, N=278 Neonatalogists, US & EU; WIN

  11. Slide 11: Significant RDS Global Revenue Opportunity

    Significant RDS Global Revenue Opportunity Regions us EU/ME LATAM China / Asia GLOBAL GS winDTtREE we U.S. Market Example: ~385,000 preterm infants per year, ~134,000 with RDS China Market: ~1.2-1.4MM preterm, ~500,000 -635,000 with RDS Estimated 2016 * Globally, only 50% to 60% of (SUL RSS RDS pati

  12. Slide 12: China Opportunity — License with Lee's Pharm

    China Opportunity — License with Lee’s Pharm = Currently, the top animal-derived surfactant sales market, but still very underpenetrated 16-19MM births / year (compared to 4MM in the U.S.) * About 1.2- 1.4MM are premature and 500,000-600,000 have RDS = New second child policy promoted by China gover

  13. Slide 13: Medical Device and Device Studies

    Medical Device and Device Studies

  14. Slide 14: Innovative Aerosol Delivery System (ADS)

    Innovative Aerosol Delivery System (ADS) Proprietary Innovative Aerosol Delivery System (ADS) Be peer Designed specifically to aerosolize and deliver KLa surfactant * AEROSURF® innovation made possible by novel medical device * Unique aerosol delivery system (ADS) technology utilizing pressure and h

  15. Slide 15: ADS Technology Provides Better Output Rate

    ADS Technology Provides Better Output Rate Aerosolizes surfactant as well as saline Aerosol output rate Output with Saline (mL/minute) Output with KL, Surfactant (30mg TPL/mL) Owe _— g 0! g 08 Eo. Eo 19 0.0 0.0 g & eo - * Saline output of ADS technology is close to KL, surfactant output of ADS techn

  16. Slide 16: Lung Deposition Study in Non-Human Primates

    Lung Deposition Study in Non-Human Primates * Use of non-human primates (cynomolgus macaques) - Nose, throat, & lung anatomy comparable to infants; respiratory function similar to preterm infants * Radiolabeled KL4 surfactant aerosolized using prototype Aerosol Delivery System (ADS), delivered via n

  17. Slide 17: AEROSURF Clinical Studies

    AEROSURF” Clinical Studies

  18. Slide 18: AEROSURF Phase Program Components

    AEROSURF” Phase 2 Program Components Study / Acti Phase 2a 2a Expansion Phase 2a Phase 2b Other Studies: Observational Study Lung Deposition Study Other Activitie: Licensing in Asia Device Development FDA Interaction Rationale / Objective Initial safety & tolerability (29-34 wk gestational age (GA))

  19. Slide 19: nCPAP Failure Through Hours by Dose Group

    45 and 60 Minute Dose Groups - nCPAP Failure through 72 hours Time to nCPAP Failure Time Until any Intubation - Dosing Group 3&4 Data 0170872016 r 100% 1 00f | y 080] 3 z z £ 009 = eee 2°" g 21/40 3 a 3 ow 2 sox | 3 8 029) é s | 20% | cl | oat — es ° ‘ x» x “ ° n CPAP Only 75 & 100 mg/kg (458.60 min

  20. Slide 20: AEROSURF Safety and Tolerability Assessment

    AEROSURF® Safety and Tolerability Assessment = The FDA requested that we conduct a separate safety study in smaller premature infants before including them in blinded studies = Multicenter, randomized, open-label, controlled study in 48 premature infants 26 to 28 weeks GA receiving nCPAP for RDS to

  21. Slide 21: Observation Related to Bronchopulmonary Dysplasia (BPD)

    Sew @ AEROSURF® Potentially Important Observation Related to Bronchopulmonary Dysplasia (BPD) 2 @: BPD Rate Patients AEROSURF 0% 0/24 Control 25% 6/24 . Bronchopulmonary Dysplasia (BPD) or chronic lung disease of the newborn is one of the most common complications of prematurity and RDS treatments.

  22. Slide 22: AEROSURF Phase 2b Trial Design

    AEROSURF* (28 to 32 wk GA) Trial Objectives Trial Design Patients Enrolled * Evaluate safety and tolerability * Demonstrate efficacy * Determine effect size for phase 3 planning * Dose(s) selection for phase 3 * Evaluate and further develop our Phase 2 prototype device performance Se wINDTREE BO Mte

  23. Slide 23: AEROSURF Phase 2b Incidence of nCPAP Failure

    AEROSURF® Phase 2b Incidence of nCPAP Failure Preplanned mITT Without Treatment Interruptions Demonstrates Targeted Reduction * US Only All Sites (to compare with 2a) 45% Aas Aas 60% 27% sox 50% 40% + relative ~ k aor reduction 38% elative 50% 7 Reduction — 35% 32% 30% 30% _ 17% 25% 10% % 0% 20' \CP

  24. Slide 24: Significantly Improved Key Respiratory Parameters

    AEROSURF® Significantly Improved Key Respiratory Parameters 08 O, Saturation / FiO, Ratio Change from Dose Init All Dosed Patient Population 80 mele os enc AP Only 40 mg/kg showed a similar pattern 04 with an intermediate effect 03 * 02 01 @ — Baseines/ Baseines/F Baseines/F 80 mg TPL kg 3.0,n=67 20

  25. Slide 25: Potential for Reduced Respiratory Support in Patients Who Failed nCPAP

    AEROSURF® - Potential for Reduced Respiratory Support in Patients Who Failed nCPAP When on AEROSURF re 20 3 10 © 0 “0 2 ° 80 mg/kg CPAP Only 80 mg/kg CPAP Only (n=27) (n=23) (n=30) (n=29) Mechanical Ventilation Supplemental Oxygen In patients who failed nCPAP and required intubation and mechanical v

  26. Slide 26: Safety & Tolerability Profile

    - Safety & Tolerability Profile Similar for Treatment and Control Populations = The adverse event and serious adverse event profile was similar across the 3 groups = Complications of prematurity were also similar 40 (4 80 kg nCPAP Only (25 min) (50 min) Acquired Sepsis 12 (17%) 13 (18%) 16 (23%) Air

  27. Slide 27: Summary of Efficacy Signals in the Phase 2 Program

    Summary of Efficacy Signals in the Phase 2 Program Post-hocpooled analysis of Phase? failurerates ‘oie = Post-hoc pooled analysis of patients inthe — 50% 20%, relative phase 2 program (3 studies) treated in 40% 36% ee ai doses > 45 minutes dosed as intended 30% (uninterrupted) shows a notablereducti

  28. Slide 28: Evolution of Aerosolized Delivery System

    Evolution of Aerosolized Delivery System from Phase 2 to the Phase 3 / Commercial Device Phase 2 Prototype * 2012-2017 * Developed in conjunction with Battelle Memorial Institute (Battelle) * Designed and used in prior phase 2 clinical experience * Battelle assembled for phase 2 trials INDTREE Curre

  29. Slide 29: Addressed Filter Issue Through Design Enhancements

    Addressed Filter Issue Through Design Enhancements, Quality Systems and Assembly. Demonstrating in a Performance Study ¥ Filter diameter doubled, surface cross section x increased by 4x v New material quality specifications and tests for flow through filter ‘ow through Ferrie ease v Modified design

  30. Slide 30: AEROSURF Clinical Development Next Steps

    AEROSURF® Clinical Development Next Steps Generate the strongest possible position and transition to phase 3 Execute a Bridge Study to transition the new, Phase 3 / Commercial ADS device in order to meet the following objectives: 1. Demonstrate adequate, consistent performance with the new ADS — Bey

  31. Slide 31: AEROSURF Bridge Study

    AEROSURF® Bridge Study = Blinded study; nCPAP alone as = Dose: Initial 100 min dose for all infants; control versus adding with up to 3 repeat doses of 50 min AEROSURF® treatment (determined by infant FiO,); minimum 20 minute assessment between doses * Ph2b was 50 min. high dose, 2 repeats = N=70 pl

  32. Slide 32: Program Evolution and Changes Intended to Increase Probability of Success

    Program Evolution and Changes Intended to Increase the Probability of Technical Success and Continue to Strengthened Data We have reproduced positive results in our Phase 2a and Phase 2b Utilize the Phase 3 / Go to Market Next Gen ADS which is designed to mitigate the risk of filter related treatmen

  33. Slide 33: Other Potential Development Activities

    Other Potential Development Activities - Lyophilized Lucinactant (LS) - Preclinical Activities EA ex 2 WINDTREE

  34. Slide 34: Opportunity to Become RDS Market Leader

    Potential Opportunity to Become RDS Market Leader with Both Non-Invasive and Invasive KL4 Surfactant Surfactant Mechanical ventilation nCPAP Support until presumpt Therapy (a) endogenous surfactant production Animal derived surfactants delivered invasively No Aerosolized surfactant available Future

  35. Slide 35: Intended Future Value Proposition and Positioning

    Intended Future Value Proposition and Positioning Windtree assets can span both treatment pathways — with one surfactant for all AEROSURF® = AEROSURF + nCPAP vs. nCPAP alone: * More efficacious than nCPAP alone * Safety benefit — noninvasive surfactant therapy reduces nCPAP failures and resulting in

  36. Slide 36: Leverage Technology to Advance Acute Pulmonary Disease Care Beyond RDS

    Leverage our Innovative Technology to Advance Acute Pulmonary Disease Care and Outcomes Beyond RDS pos ! Hise Program Focus Potential Application Eleison-ILC PecliNicalPRSSEDGRUgI ppALScelivery of | Non-small cell lung cancer, liposomal cisplatin Metastatic osteosarcoma ALI - Radiation Preclinical (

  37. Slide 37: Platform Exclusivities

    Platform Exclusivities Broad Multi-Faceted Exclusivity Portfolio Regulatory ¢ Orphan Drug Designation in RDS for the U.S. and EU =n) A ¢ AEROSURF® FDA Fast-Track Designation r sini PUROPEAN MEDICINES AGENCY = Lyophilized KL4 Surfactant Portfolio - to 2033 = Aerosol Delivery System Portfolio - throug

  38. Slide 38: 2018 Objectives

    2018 Objectives F Complete Device Development delivering an J extremely consistent, high performing Phase 3 / “go to market” drug delivery platform Solid execution of the Bridge Study AEROSURF and Lyo Lucinactant LS Global Regulatory Clarity and employed in development Successful funding supporting

  39. Slide 39: AEROSURF Development and Deliverables Overview

    AEROSURF® Development and Deliverables Overview {2019 Top Li Clinical Clinical Start Up Activities pinded) Phase 3 Start Up Acti EU Scientific Advice (___EU =Ped. Investigation Plan (PIP) ___j A Regulatory Madeal Device FDA Ped. Study Plan (PSP) j FDA — LS Advice 12018 2H 2018 through 2019 ¥ Next Ge

  40. Slide 40: Highly Experienced Management Team

    Highly Experienced Management Team bd | CEO Steve Simonson, MD Aa iw] Chief Medical Officer AstraZeneca & COVANCE DukeMedicine John Tattory EDEewsr eYOUNG &® Bristol i _ ada Mary ompicion charles SCHWAB General Counsel Kathy Cole é GytoGen 4SAVIENT Human Resourcé * George Cox ie (Pt RHONE-POULENC RO

  41. Slide 41: Value Creating Potential

    Value Creating Potential Se we WINDTREE THERAPEUTICS” = Potentially transformative therapy addressing both the unmet efficacy and safety needs in the important, acute neonatology market = Multiple phase 2 clinical trials reproducing efficacy while continuing to build a very favorable safety and tole

  42. Slide 42: Striving to deliver Hope for a Lifetime!

    “Striving to deliver Hope for a Lifetime!” Se wINDTREE we

Windtree Therapeutics — Investor Presentation (August 2018) on 6ix